financetom
Business
financetom
/
Business
/
Update: Nvidia Fiscal Q3 Non-GAAP Earnings, Revenue Rise; Q4 Outlook Set
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: Nvidia Fiscal Q3 Non-GAAP Earnings, Revenue Rise; Q4 Outlook Set
Nov 20, 2024 7:41 PM

05:02 PM EST, 11/20/2024 (MT Newswires) -- (Updates the stock change in the last paragraph.)

Nvidia ( NVDA ) reported fiscal Q3 non-GAAP earnings late Wednesday of $0.81 per diluted share, up from $0.40 a year earlier.

Analysts polled by FactSet expected $0.75 excluding some items.

Revenue in the three months ended Oct. 27 rose to $35.08 billion from $18.12 billion a year earlier.

Analysts surveyed by FactSet expected $33.17 billion.

The company expects fiscal Q4 revenue of $37.5 billion, plus or minus 2%. Analysts expect $37.09 billion.

Nvidia ( NVDA ) shares fell 0.7% in after-hours activity, paring earlier losses.

Price: 144.81, Change: -1.08, Percent Change: -0.74

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Loblaw Companies Q3 Adjusted Earnings, Revenue, Beat Estimates
Loblaw Companies Q3 Adjusted Earnings, Revenue, Beat Estimates
Nov 12, 2025
07:14 AM EST, 11/12/2025 (MT Newswires) -- Loblaw Companies ( LBLCF ) said Wednesday that third-quarter adjusted earnings and revenue both rose, with both measures beating estimates. Adjusted earnings increased 8% to $828 million or $0.69 per diluted share, from $767 million, or $0.62 per diluted share in the prior year period. The result was a cent above the consensus...
TScan Therapeutics Q3 revenue jumps
TScan Therapeutics Q3 revenue jumps
Nov 12, 2025
Overview * TScan Q3 2025 revenue rose to $2.5 mln, driven by collaboration agreements * Net loss for Q3 2025 increased due to higher R&D expenses * Company reached FDA agreement on pivotal trial design for TSC-101 Outlook * Company expects cash reserves to fund operations into the second half of 2027 * Enrollment in solid tumor trial paused to...
ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team
ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team
Nov 12, 2025
$142.6 million cash and cash equivalents and marketable securities as of September 30, 2025  Protocol amendment for ongoing Phase 2b ADAPTIVE study of IMG-007 in atopic dermatitis (AD) announced to optimize study design in alignment with IMG-007’s unique molecular attributes; strong patient enrollment continues Novel alopecia areata data including biomarkers from Phase 1b/2a study to be presented at upcoming Inflammatory...
Ovid Therapeutics Q3 revenue slightly beats expectations
Ovid Therapeutics Q3 revenue slightly beats expectations
Nov 12, 2025
Overview * Ovid Therapeutics ( OVID ) Q3 revenue slightly beats analyst expectations * Meg Alexander appointed CEO, effective January 2026 Outlook * Ovid plans Phase 2a trial for OV329 in Q2 2026 * Company expects OV350 data in Q4 2025 * Ovid anticipates OV4071 clinical trial start in Q2 2026 Result Drivers * Research and development expenses were $5.9...
Copyright 2023-2026 - www.financetom.com All Rights Reserved